Drug interactions
Alogliptin-pioglitazone + Ponatinib
Severity: Minor
Alogliptin-pioglitazone and Ponatinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pioglitazone is not a recognized clinically important OATP1B1 inhibitor, so a meaningful effect on ponatinib is not established. Ponatinib can cause hyperglycemia and hepatotoxicity, which may affect diabetes control and liver monitoring.
What this interaction means in plain words
Alogliptin-pioglitazone and Ponatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Alogliptin-pioglitazone belongs to Endocrine; Ponatinib belongs to Oncology.
Why it happens
No established pharmacokinetic mechanism; theoretical transporter interaction only.
What to do
Monitor blood glucose and liver enzymes during ponatinib therapy.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Alogliptin-pioglitazone and Ponatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Alogliptin-pioglitazone
Other interactions of Ponatinib
Frequently asked questions
Can I take Alogliptin-pioglitazone with Ponatinib?
MediHelp rates the interaction as minor. Alogliptin-pioglitazone and Ponatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Pioglitazone is not a recognized clinically important OATP1B1 inhibitor, so a meaningful effect on ponatinib is not established. Ponatinib can cause hyperglycemia and hepatotoxicity, which may affect diabetes control and liver monitoring.
How serious is the interaction between Alogliptin-pioglitazone and Ponatinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose and liver enzymes during ponatinib therapy.
What other medicines interact with Alogliptin-pioglitazone?
MediHelp also lists interactions of Alogliptin-pioglitazone with, for example, Gemfibrozil, Insulin aspart, Insulin degludec. The full list is on the Alogliptin-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
